MwanzoGBT • EPA
add
Guerbet SA
Bei iliyotangulia
€ 14.78
Bei za siku
€ 14.58 - € 14.90
Bei za mwaka
€ 12.72 - € 39.35
Thamani ya kampuni katika soko
188.35M EUR
Wastani wa hisa zilizouzwa
elfu 42.85
Uwiano wa bei na mapato
36.66
Mgao wa faida
-
Ubadilishanaji wa msingi
EPA
Habari za soko
Kalkine Media
saa 1 iliyopita
Power Corporation of Canada (TSX:POW) Visibility S&P TSX Composite Index
0.00%
0.00%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 197.36M | -7.11% |
Matumizi ya uendeshaji wa biashara | 149.62M | -3.00% |
Mapato halisi | 1.32M | -76.01% |
Kiwango cha faida halisi | 0.67 | -74.03% |
Mapato kwa kila hisa | — | — |
EBITDA | 22.20M | -26.51% |
Asilimia ya kodi ya mapato | 50.97% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 50.12M | 28.36% |
Jumla ya mali | 1.02B | -2.39% |
Jumla ya dhima | 644.94M | -1.44% |
Jumla ya hisa | 372.13M | — |
hisa zilizosalia | 12.60M | — |
Uwiano wa bei na thamani | 0.50 | — |
Faida inayotokana na mali | 1.84% | — |
Faida inayotokana mtaji | 2.42% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 1.32M | -76.01% |
Pesa kutokana na shughuli | 11.27M | 121.77% |
Pesa kutokana na uwekezaji | -7.74M | 34.85% |
Pesa kutokana na ufadhili | -2.44M | -335.94% |
Mabadiliko halisi ya pesa taslimu | elfu -123.50 | 97.98% |
Mtiririko huru wa pesa | 14.24M | 44.21% |
Kuhusu
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.
In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters, formerly located in Villepinte, is currently located in Chicago, and its shares are included in the NASDAQ stock index.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015.
In 2022, the United States Food and Drug Administration approved Guerbet Group's Elucirem, an MRI contrast agent. The product will be produced at Guerbet's factory in Raleigh, North Carolina and at three of its French factories.
An analysis of the growing global contrast media market, valued at $6.19 billion 2023 US dollars described Guerbet as a "key player." Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1926
Tovuti
Wafanyakazi
2,842
